Genoscience Pharma Is Innovating to Disrupt Cancer Treatment

We are conceptualizing and developing disruptive and innovative science from bench to bedside for improving the conditions of patients in serious unmet medical needs.

Our Approach

As all human living cells, cancer cells need energy to self-renew and survive. Lysosome is a key compartment implicated in cancer cells survival. Among the acquired modifications in cancer cells, changes in lysosomal phenotype and functions are well described, making lysosome a target of interest for novel therapies. Genoscience Pharma focuses on new approaches based on the depriving of cancer cells from essential nutrients by disrupting lysosomal functions.

Discover

Our Pipeline

We leverage our deep knowledge of underlying biological processes to develop innovative and disruptive technology, with potent small molecule drug candidates that directly target lysosomal functions, implicated in the growth, spread and resistance of cancers. We retain global development and commercialization rights of GNS561.

Discover

News

News
January 13, 2020

ISO9001:2015 Certification for our R&D and Clinical Activities in Oncology

Marseille, January 13, 2020 - Genoscience Pharma, a clinical-stage biotechnology company dedicated to discovering and…
Read More
News
December 16, 2019

GNS561 to treat pancreas or colorectal cancer with liver metastasis

GENOSCIENCE PHARMA Announces Extension of GNS561 Phase 1/2 Clinical Trial to Patients with Pancreas or…
Read More
News
November 14, 2019

Outstanding Data on GNS561 in Combination with a PD-1 Inhibitor

Outstanding Data on GNS561 in Combination with a PD-1 Inhibitor to Be Presented at the…
Read More

Events

Events
January 13-15, 2020

Biotech Showcase™ 2020

Biotech Showcase™ 2020 - San Francisco, California Investor conference   We will be present during…
Read More
Events
December 2, 2019

The GoforIsrael Investment Conference 2019

The GoforIsrael - Investment Conference 2019 - Tel Aviv, Israel   We are honored to…
Read More
Events
November 8-12, 2019

The AASLD Liver Meeting 2019

The AASLD - Liver Meeting 2019 - Boston, Massachusetts, USA   We have the pleasure…
Read More

“Translating novel scientific insights into medicines for cancer patients”

Philippe Halfon, CEO of Genoscience Pharma